Literature DB >> 31933223

Margin Positivity in Resectable Esophageal Cancer: Are there Modifiable Risk Factors?

Cary Jo R Schlick1, Rhami Khorfan1, David D Odell1, Ryan P Merkow1,2, David J Bentrem3,4.   

Abstract

BACKGROUND: Patients with esophageal cancer have poor overall survival, with positive resection margins worsening survival. Margin positivity rates are used as quality measures in other malignancies, but modifiable risk factors are necessary to develop actionable targets for improvement. Our objectives were to (1) evaluate trends in esophageal cancer margin positivity, and (2) identify modifiable patient/hospital factors associated with margin positivity.
METHODS: Patients who underwent esophagectomy from 2004 to 2015 were identified from the National Cancer Database. Trends in margin positivity by time and hospital volume were evaluated using Cochrane-Armitage tests. Associations between patient/hospital factors and margin positivity were assessed by multivariable logistic regression.
RESULTS: Among 29,706 patients who underwent esophagectomy for cancer, 9.37% had positive margins. Margin positivity rates decreased over time (10.62% in 2004 to 8.61% in 2015; p < 0.001). Older patients (≥ 75 years) were more likely to have positive margins [odds ratio (OR) 2.04, 95% confidence interval (CI) 1.42-2.92], as were patients with a Charlson-Deyo Index ≥ 3 (OR 1.84, 95% CI 1.08-3.12). Patients who received neoadjuvant therapy were less likely to have positive margins (OR 0.37, 95% CI 0.29-0.47), while laparoscopic surgical approach was associated with increased margin positivity (OR 1.70, 95% CI 1.40-2.06). As the hospital annual esophagectomy volume increased, margin positivity rates decreased (7.76% in the fourth quartile vs. 11.39% in the first quartile; OR 0.70, 95% CI 0.49-0.99).
CONCLUSIONS: Use of neoadjuvant therapy, surgical approach, and hospital volume are modifiable risk factors for margin positivity in esophageal cancer. These factors should be considered in treatment planning, and margin positivity rates could be considered as a quality measure in esophageal cancer.

Entities:  

Mesh:

Year:  2020        PMID: 31933223      PMCID: PMC7321808          DOI: 10.1245/s10434-019-08176-z

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  49 in total

1.  Trends in hospital volume and operative mortality for high-risk surgery.

Authors:  Jonathan F Finks; Nicholas H Osborne; John D Birkmeyer
Journal:  N Engl J Med       Date:  2011-06-02       Impact factor: 91.245

Review 2.  What is the role for the circumferential margin in the modern treatment of rectal cancer?

Authors:  Iris D Nagtegaal; Phil Quirke
Journal:  J Clin Oncol       Date:  2008-01-10       Impact factor: 44.544

3.  Associated risk factor analysis for positive resection margins after endoscopic submucosal dissection in early-stage gastric cancer.

Authors:  Jing Wen; En-Qiang Linghu; Yun-Sheng Yang; Qing-Sen Liu; Jing Yang; Zhong-Sheng Lu
Journal:  J BUON       Date:  2015 Mar-Apr       Impact factor: 2.533

4.  Surgical and long-term outcomes following oesophagectomy in oesophageal cancer patients with comorbidity.

Authors:  Hiroshi Ichikawa; Shin-Ichi Kosugi; Tatsuo Kanda; Kazuhito Yajima; Takashi Ishikawa; Takaaki Hanyu; Yusuke Muneoka; Takahiro Otani; Masayuki Nagahashi; Jun Sakata; Takashi Kobayashi; Hitoshi Kameyama; Toshifumi Wakai
Journal:  Int J Surg       Date:  2016-10-31       Impact factor: 6.071

Review 5.  Variation in the standard of minimally invasive esophagectomy for cancer--systematic review.

Authors:  George B Hanna; Shobhit Arya; Sheraz R Markar
Journal:  Semin Thorac Cardiovasc Surg       Date:  2012

Review 6.  Minimally invasive oesophagectomy versus open surgery: is there an advantage?

Authors:  Lesley Uttley; Fiona Campbell; Michael Rhodes; Anna Cantrell; Heather Stegenga; Myfanwy Lloyd-Jones
Journal:  Surg Endosc       Date:  2012-10-06       Impact factor: 4.584

Review 7.  Multidisciplinary management of rectal cancer: the OSTRICH.

Authors:  David W Dietz
Journal:  J Gastrointest Surg       Date:  2013-07-25       Impact factor: 3.452

Review 8.  Volume-outcome relationship in surgery for esophageal malignancy: systematic review and meta-analysis 2000-2011.

Authors:  Sheraz R Markar; Alan Karthikesalingam; Sri Thrumurthy; Donald E Low
Journal:  J Gastrointest Surg       Date:  2011-11-17       Impact factor: 3.452

9.  Minimally invasive versus open oesophagectomy for patients with oesophageal cancer: a multicentre, open-label, randomised controlled trial.

Authors:  Surya S A Y Biere; Mark I van Berge Henegouwen; Kirsten W Maas; Luigi Bonavina; Camiel Rosman; Josep Roig Garcia; Suzanne S Gisbertz; Jean H G Klinkenbijl; Markus W Hollmann; Elly S M de Lange; H Jaap Bonjer; Donald L van der Peet; Miguel A Cuesta
Journal:  Lancet       Date:  2012-05-01       Impact factor: 79.321

10.  Adenocarcinoma of the gastroesophageal junction: influence of esophageal resection margin and operative approach on outcome.

Authors:  Andrew P Barbour; Nabil P Rizk; Mithat Gonen; Laura Tang; Manjit S Bains; Valerie W Rusch; Daniel G Coit; Murray F Brennan
Journal:  Ann Surg       Date:  2007-07       Impact factor: 12.969

View more
  1 in total

1.  Clinical impact of remnant lymphatic invasion on the recurrence of esophageal squamous cell carcinoma after esophagectomy with neoadjuvant chemotherapy.

Authors:  Sho Okuda; Kenoki Ohuchida; Koji Shindo; Taiki Moriyama; Jun Kawata; Koji Tamura; Masafumi Sada; Kinuko Nagayoshi; Yusuke Mizuuchi; Naoki Ikenaga; Kohei Nakata; Yoshinao Oda; Masafumi Nakamura
Journal:  Oncol Lett       Date:  2022-08-11       Impact factor: 3.111

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.